ANN ARBOR, Mich., May 1, 2008 (PRIME NEWSWIRE) -- MIR Preclinical Services (MIR) has been recognized as one of the Michigan's 50 top companies to watch. This prestigious award is developed by the Edward Lowe Foundation and the State of Michigan to honor second-stage companies that demonstrate high performance in the marketplace, exhibit innovative products or processes, or otherwise make those companies "worth watching."
Frank Urban, the Senior Manager of Business Development at MIR accepted this award on behalf of the company in the state capital of Lansing last week. "It was an honor to accept this award on behalf of everyone at MIR who made this possible," Mr. Urban stated. "We have worked hard to develop an organization that combines quality science and unsurpassed service. It is nice to have this dedication recognized not only by our clients but the State of Michigan as well. We have come a long way since our inception. I was the ninth employee when I started with the company in May of 2004. By the end of 2008 we expect to have 35 employees, 30 of which will be experienced scientists. Though we are growing rapidly, our commitment to scientific values, quality and customer service remains our focus," Mr. Urban concluded.
About MIR Preclinical Services
MIR is a contract research organization specializing in the preclinical assessments and evaluation of novel anti-cancer and anti-inflammatory therapeutic agents. The company's senior leadership has over 100 years of drug discovery experience with models of cancer and inflammatory diseases. MIR offers many services that include analysis of efficacy, pharmacodynamics, pharmacokinetics, blood chemistries and histology. This is in addition to non-invasive imaging of disease status at anatomical and functional levels and consulting. MIR is a leader in the integration of traditional efficacy testing with clinically relevant imaging technologies to provide new insights to drug discovery and development. The company is unique in its ability to apply non-invasive in vivo imaging modalities including preclinical MRI, X-ray micro-CT, high resolution preclinical PET, and bioluminescence and fluorescence imaging to visualize biological processes such as signal transduction, apoptosis, angiogenesis, bone deformation, joint degradation and tumor growth. MIR actively collaborates with leading scientists in developing new drug evaluation technologies with a view to publication of results in peer reviewed journals.